Sign In
Buy ATNX
$0.203
+0 (+0%)
At Close: Aug 23, 2023
Athenex (ATNX) Reports Q3 Loss, Tops Revenue Estimates
12:13pm, Thursday, 04'th Nov 2021
Athenex (ATNX) delivered earnings and revenue surprises of 19.51% and 66.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Athenex (ATNX) Sees Hammer Chart Pattern: Time to Buy?
08:26am, Wednesday, 03'rd Nov 2021
Athenex (ATNX) has been struggling lately, but the selling pressure may be coming to an end soon.
Athenex and the Center for Cell and Gene Therapy Announce Allowance of Our First U.S. Patent Claims Around CAR-NKT Cell Therapy
08:15am, Monday, 18'th Oct 2021
Patent includes a pharmaceutical composition claim comprising a plurality of genetically modified CD62L-positive human NKT cells comprising at least one chimeric antigen receptor (CAR)
After Plunging 25.6% in 4 Weeks, Here's Why the Trend Might Reverse for Athenex (ATNX)
01:23pm, Tuesday, 12'th Oct 2021
Athenex (ATNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates c
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic Breast Cancer
08:00am, Monday, 11'th Oct 2021
BUFFALO, N.Y., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the tr
5 Penny Stocks To Buy According To Insiders In September
01:31pm, Thursday, 16'th Sep 2021
Insiders are buying shares of these penny stocks this months; are you? The post 5 Penny Stocks To Buy According To Insiders In September appeared first on Penny Stocks to Buy, Picks, News and Informat
Athenex Shares Are Trading Higher On Positive Oral Paclitaxel Data From Solid Tumor Trial
08:04am, Thursday, 16'th Sep 2021
Athenex Inc (NASDAQ: ATNX) announced data presentation from a Phase 1 study evaluating encequidar (Oral Paclitaxel) in combination with Merck Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in adva
Athenex Presents Data from Oral Paclitaxel + Pembrolizumab Phase 1 Study at ESMO 2021
02:30am, Thursday, 16'th Sep 2021
Safety Data Help Establish Part B Dose Expansion and Phase 2 Dose; Data showed encouraging anti-tumor activity (4 PR out of 8 evaluable patients) in NSCLC patients who failed prior PD1/PDL1 therapies
Athenex: Is This Stock A Buy, Sell, Or Hold? It's A Hold.
05:19pm, Tuesday, 31'st Aug 2021
Athenex, Inc. is a biopharmaceutical company developing and commercializing next-generation drugs for treating various cancers. Athenex's pipeline consists of four therapeutic programs, Orascovery (P-
Athenex, Inc. (ATNX) CEO Johnson Lau on Q2 2021 Results - Earnings Call Transcript
06:21pm, Saturday, 07'th Aug 2021
Athenex, Inc. (ATNX) CEO Johnson Lau on Q2 2021 Results - Earnings Call Transcript
Athenex Provides Second Quarter 2021 Corporate and Financial Update
07:00am, Thursday, 05'th Aug 2021
Updated investors on FDA Type A Meeting for oral paclitaxel
Athenex Announces Additional Licensing Agreements for Tirbanibulin
07:00am, Monday, 26'th Jul 2021
Athenex expands its international commercial partnerships for tirbanibulin in Australia, New Zealand and Canada Athenex expands its international commercial partnerships for tirbanibulin in Australia,
Athenex to Provide Corporate and Financial Update for the Second Quarter 2021 on August 5, 2021
08:47am, Thursday, 22'nd Jul 2021
BUFFALO, N.Y., July 22, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for
Athenex Announces European Commission Approval of Klisyri® (tirbanibulin) for the Topical Treatment of Actinic Keratosis
10:51am, Monday, 19'th Jul 2021
BUFFALO, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for
Athenex Issues Update On Oral Paclitaxel Application In Metastatic Breast Cancer
09:20am, Tuesday, 06'th Jul 2021
Athenex Inc (NASDAQ: ATNX) held a Type A meeting with the FDA during the second quarter of 2021 to discuss the deficiencies raised in the Complete Response Letter (CRL) regarding application for or
